MetaVia Inc. (NASDAQ:MTVA – Free Report) – Zacks Research issued their Q1 2026 earnings per share estimates for shares of MetaVia in a research note issued to investors on Tuesday, March 31st. Zacks Research analyst D. Bautz expects that the company will earn ($0.74) per share for the quarter. The consensus estimate for MetaVia’s current full-year earnings is ($3.90) per share. Zacks Research also issued estimates for MetaVia’s Q2 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($1.53) EPS and FY2028 earnings at ($1.43) EPS.
A number of other research analysts have also issued reports on MTVA. Weiss Ratings reiterated a “sell (d-)” rating on shares of MetaVia in a research report on Monday, December 22nd. Wall Street Zen raised shares of MetaVia from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Finally, HC Wainwright reduced their price objective on shares of MetaVia from $40.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, March 27th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, MetaVia currently has an average rating of “Hold” and a consensus target price of $26.50.
MetaVia Trading Up 0.8%
Shares of MTVA opened at $1.26 on Thursday. The firm has a market cap of $2.77 million, a P/E ratio of -0.15 and a beta of 0.35. MetaVia has a 12 month low of $1.17 and a 12 month high of $23.10. The stock’s 50 day moving average is $1.67 and its two-hundred day moving average is $6.63.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC bought a new position in MetaVia Inc. (NASDAQ:MTVA – Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The firm bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia at the end of the most recent reporting period. Institutional investors own 1.37% of the company’s stock.
About MetaVia
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.
See Also
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
